2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-P1195
    PDZ1 Domain inhibitor peptide 1315378-73-4 99.04%
    PDZ1 Domain inhibitor peptide, a cyclic peptide, incorporates a β-Ala lactam side chain linker and targets the PDZ1 domains of the postsynaptic density protein 95 (PSD-95). PDZ1 Domain inhibitor peptide disrupts the GluR6/PSD-95 interaction and is very efficient in competing against the C terminus of GluR6 for the PDZ1 domain.
    PDZ1 Domain inhibitor peptide
  • HY-P1255
    Kinetensin 103131-69-7 99.89%
    Kinetensin is a neurotensin-like peptide isolated from pepsin-treated human plasma.
    Kinetensin
  • HY-P1278
    GR 64349 137593-52-3 99.92%
    GR 64349 is a potent and highly selective NK2 receptor peptide antagonist, with an EC50 of 3.7 nM in rat colon. GR 64349 exhibits selectivity >1000 and >300-fold with respect to NK1 and NK3 receptors, respectively.
    GR 64349
  • HY-P1294
    α-Helical CRF(9-41) 90880-23-2 99.44%
    α-Helical CRF(9-41) is a competitive CRF2 receptor antagonist with KB of ~100 nM. α-Helical CRF(9-41) is also a partial agonist of CRF1 receptor with an EC50 of 140 nM.
    α-Helical CRF(9-41)
  • HY-P1302
    Orphanin FQ(1-11) 178249-41-7 99.52%
    Orphanin FQ(1-11), a orphanin FQ or nociceptin (OFQ/N) fragment, is a potent NOP receptor (ORL-1; OP4) agonist, with a Ki of 55 nM. Orphanin FQ(1-11) has no affinity for μ, δ, κ1 and κ3 receptors (Ki>1000 nM). Orphanin FQ(1-11) is analgesic in CD-1 mice.
    Orphanin FQ(1-11)
  • HY-P1349
    Orexin B, rat, mouse 202801-92-1
    Orexin B, rat, mouse (Rat orexin B) is an endogenous agonist at Orexin receptor with Kis of 420 and 36 nM for OX1 and OX2, respectively.
    Orexin B, rat, mouse
  • HY-P1373
    Neuronostatin-13 (human) 1096485-24-3 98.72%
    Neuronostatin-13 human is a 13-amino acid peptide hormone encoded by the somatostatin gene and plays an important role in the regulation of hormonal and cardiac function.
    Neuronostatin-13 (human)
  • HY-P1470
    [Leu5]-Enkephalin, amide 60117-24-0
    [Leu5]-Enkephalin, amide is a δ opioid receptor agonist.
    [Leu5]-Enkephalin, amide
  • HY-P1499
    Somatostatin-28 (1-14) 79243-10-0 99.56%
    Somatostatin-28 (1-14) is an N-terminal fragment of the neuropeptide somatostatin-28.
    Somatostatin-28 (1-14)
  • HY-P1517
    β-Amyloid (31-35) 149385-65-9 99.10%
    β-Amyloid (31-35) is the shortest sequence of native Amyloid-β peptide that retains neurotoxic activity.
    β-Amyloid (31-35)
  • HY-P1525
    Melanin Concentrating Hormone, salmon 87218-84-6 98.40%
    Melanin Concentrating Hormone, salmon is a 19-amino-acid neuropeptide initially identified in the pituitary gland of teleost fish, which regulates food intake, energy balance, sleep state, and the cardiovascular system. Melanin-concentrating hormone is a ligand for an orphan G protein-coupled receptor (SLC-1/GPR24) and MCHR2.
    Melanin Concentrating Hormone, salmon
  • HY-P1764
    Secretoneurin, rat 149146-12-3 99.59%
    Secretoneurin, rat, a 33-amino acid polypeptide, is generated by proteolytic processing of secretogranin II (SgII). Secretoneurin, rat induces dopamine release in the rat striatum in vivo and in vitro, and it exerts a very strong chemotactic effect on monocytes and eosinophils but not on granulocytes.
    Secretoneurin, rat
  • HY-P1765
    Galanin (1-19), human 136005-51-1 98.90%
    Galanin (1-19), human is the 1-19 fragment of the human galanin. Galanin (GAL) is a widely distributed neuropeptide with diverse biological effects including modulation of hormone release, antinociception and modification of feeding behavior.
    Galanin (1-19), human
  • HY-P1831
    Proadrenomedullin (1-20), human 150238-87-2 99.71%
    Proadrenomedullin (1-20), human is a potent hypotensive and catecholamine release–inhibitory peptide released from chromaffin cells with an IC50 of ~350 nM for catecholamine secretion in PC12 pheochromocytoma cells, acting in a noncompetitive manner specifically at the nicotinic cholinergic receptor.
    Proadrenomedullin (1-20), human
  • HY-P2259
    TAT-GluA2 3Y 1404188-93-7 99.95%
    TAT-GluA2 3Y, an interference peptide, blocks long-term depression (LTD) at glutamatergic synapses by disrupting the endocytosis of AMPAR. TAT-GluA2 3Y can alleviate Pentobarbital-induced spatial memory deficits and synaptic depression.
    TAT-GluA2 3Y
  • HY-P5111
    Myristoyl-(Lys12,27,28)-VIP-Gly-Gly-Thr free acid 2243219-86-3 98.12%
    Myristoyl-(Lys12,27,28)-VIP-Gly-Gly-Thr (free acid) is a high-affinity and selective VPAC2 receptor antagonist.
    Myristoyl-(Lys12,27,28)-VIP-Gly-Gly-Thr free acid
  • HY-P6374
    IIQLPEIVVV TFA 99.91%
    IIQLPEIVVV TFA is a specific inhibitor of Drp1-Mff interaction. IIQLPEIVVV TFA can distinguish physiological from pathological fission and block physiological fission, thus leading to mitochondrial dysfunction. IIQLPEIVVV TFA can be used in the study of Huntington's disease.
    IIQLPEIVVV TFA
  • HY-P9995
    Posdinemab 2517973-04-3 ≥99.0%
    Posdinemab (JNJ-63733657) is a humanized IgG1/κ monoclonal antibody that selectively targets phosphorylated tau (pT217). Posdinemab specifically binds to the pT217+tau epitope rich in the proline domain, blocks tau protein aggregation and seed propagation, and promotes the clearance of extracellular tau species. Posdinemab reduces the levels of free and total p217+tau in cerebrospinal fluid, thereby inhibiting the pathological propagation of tau protein and the formation of neurofibrillary tangles. Posdinemab can be used for the study of progressive supranuclear palsy syndrome and Alzheimer's disease (AD), especially for prodromal or mild AD disease.
    Posdinemab
  • HY-Y1322
    Triphenyl phosphate 115-86-6 ≥98.0%
    Triphenyl phosphate is an organic phosphate flame retardant. Triphenyl phosphate can disrupt placental tryptophan metabolism by activating MAOA/ROS/NFκB, leading to abnormal neurological behavior. Triphenyl phosphate promotes oxidative stress by inducing inflammatory factors like nuclear factor kappa B (NFκB), interleukin-6, and tumor necrosis factor α. Triphenyl phosphate can also cause allergic contact dermatitis.
    Triphenyl phosphate
  • HY-100372
    E4CPG 170846-89-6 ≥98.0%
    E4CPG ((RS)-ECPG) is a Group I/Group II metabotropic glutamate receptor (mGluR) antagonist. E4CPG can inhibit the paired-pulse ratio of monosynaptic inhibitory postsynaptic currents (IPSC) potentiation.
    E4CPG
Cat. No. Product Name / Synonyms Application Reactivity